Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	57.37B
Revenue (ttm)	4.27B
Net Income (ttm)	308.94M
Shares Out	1.11B
EPS (ttm)	0.27
PE Ratio	190.31
Forward PE	109.27
Dividend	0.42 (0.80%)
Ex-Dividend Date	May 15, 2025

Volume	5,731,717
Average Volume	4,513,931
Open	50.36
Previous Close	51.70
Day's Range	50.36 - 54.28
52-Week Range	29.13 - 62.65
Beta	-0.19
RSI	44.34
Earnings Date	Oct 29, 2025

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylpre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 5,337
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2024, SHE:002653's revenue was 3.72 billion, an increase of 10.92% compared to the previous year's 3.36 billion. Earnings were 395.46 million, an increase of 34.00%.